Dose-dependent Bioavailability
Dose-Dependent Bioavailability is a pharmacokinetic phenomenon in which the systemic exposure of a drug changes disproportionately with alterations in administered dose, distinguished from dose-independent bioavailability by its reliance on nonlinear absorption, distribution, metabolism, or excretion processes.
77
Publications
3.8K
Citations
452
Authors
153
Institutions
Publications per year
2017–2026
19
Parents
77
Clinical pharmacokinetics of gabapentin.
Michael J. McLean · PubMed · 1994 · 263 citations
Johan Karlsson, Shiu‐Ming Kuo, John A. Ziemniak et al. · British Journal of Pharmacology · 1993 · 180 citations · Full text
Medicine, Cell Biology, Pharmacology +17
Veronika Somoza, Elisabeth Wenzel, Carola Weiß et al. · Molecular Nutrition & Food Research · 2006 · 125 citations
1–5 of 77
452
2
h-index
1
h-index
1
h-index
1
h-index
1
h-index
1–5 of 452
153

Universidad de Montevideo
Montevideo, Uruguay
2 h-index
4 publications
59 citations
Bristol-Myers Squibb (United States)
New York, United States
2 h-index
36 publications
1.8K citations
University of Florida
Gainesville, United States
2 h-index
5 publications
98 citations

Uppsala University
Uppsala, Sweden
2 h-index
3 publications
370 citations
Oregon State University
Corvallis, United States
2 h-index
11 publications
400 citations

King Saud University
Riyadh, Saudi Arabia
2 h-index
3 publications
70 citations
University at Buffalo, State University of New York
Buffalo, United States
2 h-index
3 publications
310 citations
Pfizer (United States)
New York, United States
2 h-index
7 publications
161 citations
1–8 of 153
Repository · 9 publications · 401 citations
9
h-index
CPT · 4 publications · 251 citations
4
h-index
3 publications · 156 citations
3
h-index
3 publications · 62 citations
3
h-index
2 publications · 37 citations
2
h-index
1–5